Details of the Drug Combinations

General Information of This Drug (ID: DMTL94F)

• Drug Name: Maraviroc (DMTL94F)
• Synonyms: 376348-65-1; Selzentry; Celsentri; UK-427857; UK-427,857; UK 427857; UNII-MD6P741W8A; MD6P741W8A; CHEMBL256907; MVC; CHEMBL1201187; CHEBI:63608; 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[321]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide; Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide; Maraviroc [USAN]; Celsentri (TN); Celsentri(TM); PRO 140 & Maraviroc; Selzentry (TN); Selzentry(TM); UK-427,857 maraviroc (MVC); Exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[321]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide; 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(321)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide; [3H]maraviroc

Indication

Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]; Chronic obstructive pulmonary disease; ICD 11: CA22; Status: Phase 3 [1]

• Therapeutic Class: Anti-HIV Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

56 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Acamprosate + Maraviroc	DCJ21ID	Acamprosate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Arfolitixorin + Maraviroc	DCHOR2M	Arfolitixorin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Bortezomib + Maraviroc	DCK2432	Bortezomib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Dantrolene + Maraviroc	DCDJGTI	Dantrolene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Darunavir + Maraviroc	DC0HZXQ	Darunavir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Docetaxel + Maraviroc	DCFB3PK	Docetaxel	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Fenoprofen + Maraviroc	DC7FJAK	Fenoprofen	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Leflunomide + Maraviroc	DCTQZYJ	Leflunomide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Levamisole + Maraviroc	DCZ076Q	Levamisole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Lithium Citrate + Maraviroc	DCJ2OWA	Lithium Citrate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Gefitinib	DC27S4C	Gefitinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Diethylcarbamazine	DC6QIRQ	Diethylcarbamazine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Triamterene	DCREAJA	Triamterene	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Epinephrine	DCGTETW	Epinephrine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + PMID28460551-Compound-2	DCGZ14H	PMID28460551-Compound-2	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Panobinostat	DCU959G	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Maraviroc + Methotrexate	DCKGHQ0	Methotrexate	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Fomepizole	DCH7ECM	Fomepizole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Ramelteon	DCPSZPS	Ramelteon	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Triapine	DC483TJ	Triapine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + BHV-0223	DC5JJSC	BHV-0223	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Metyrosine	DCH84HT	Metyrosine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Efavirenz	DCTV9HY	Efavirenz	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Chlorzoxazone	DC7DUX4	Chlorzoxazone	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Phensuximide	DC4GQFZ	Phensuximide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + VR-776	DCENQ5M	VR-776	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Naringenin	DCD9EX6	Naringenin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + PFK-158	DCWAZ49	PFK-158	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Tiagabine	DC1OUGZ	Tiagabine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Diazoxide	DC0E7FB	Diazoxide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Idarubicin	DCWPCHK	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
Maraviroc + Imatinib	DCWK65A	Imatinib	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Pramipexole	DC554V1	Pramipexole	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Methylene blue	DCIPVU5	Methylene blue	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Maprotiline	DCXPFUL	Maprotiline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Theophylline	DC4T1RA	Theophylline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Acarbose	DCI6W5T	Acarbose	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Brincidofovir	DCPX36G	Brincidofovir	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Hyodeoxycholic acid	DCQYABG	Hyodeoxycholic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Mycophenolic acid	DCVTEPD	Mycophenolic acid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Mefloquine	DC5GKNZ	Mefloquine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Lacosamide	DCEKLDG	Lacosamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Auranofin	DCBD8VA	Auranofin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Rufinamide	DCKW4X6	Rufinamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + FORMESTANE	DC0AGBX	FORMESTANE	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Vorinostat	DC0IE4Q	Vorinostat	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Cevimeline	DC6AXC2	Cevimeline	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Cerivastatin	DCMI9P1	Cerivastatin	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Maraviroc + Azatadine	DC8PCN5	Azatadine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
ML323 + Maraviroc	DCK3VFP	ML323	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Pentamidine + Maraviroc	DC9WUT0	Pentamidine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Probenecid + Maraviroc	DCLYCZA	Probenecid	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Trihexyphenidyl + Maraviroc	DC4PQDC	Trihexyphenidyl	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Trimethobenzamide + Maraviroc	DCPJCI2	Trimethobenzamide	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Vinblastine + Maraviroc	DCRJ3WM	Vinblastine	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]
Zileuton + Maraviroc	DCRE4XO	Zileuton	Chronic myelogenous leukemia (Cell Line: KBM-7)	[2]

15 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Atazanavir + Maraviroc	DC4NSKF	Atazanavir	HIV Infections	[3]
Dolutegravir + Maraviroc	DC3W8PO	Dolutegravir	Chronic Infection	[4]
Dolutegravir + Maraviroc	DCC6D7R	Dolutegravir	Chronic Infection	[4]
Emtricitabine + Maraviroc	DCPOUHM	Emtricitabine	HIV Infection	[5]
Etravirine + Maraviroc	DC70SA6	Etravirine	HIV Infections	[3]
Lopinavir + Maraviroc	DCE11ZR	Lopinavir	HIV Infections	[3]
Tenofovir disoproxil + Maraviroc	DC89Z0H	Tenofovir disoproxil	HIV Infection	[5]
Vardenafil + Maraviroc	DCK64FG	Vardenafil	AIDS	[6]
Darunavir + Maraviroc	DCPAGJO	Darunavir	HIV-1 Infection	[7]
Methotrexate + Maraviroc	DCZMDCP	Methotrexate	Graft-versus-host Disease	[8]
Methotrexate + Maraviroc	DCWL1XT	Methotrexate	Acute Leukemia	[9]
Dolutegravir + Maraviroc	DCLUVJC	Dolutegravir	HIV Infections	[10]
Saquinavir + Maraviroc	DCGCSIW	Saquinavir	Human Immunodeficiency Virus (HIV) Infection	[11]
Saquinavir + Maraviroc	DCICI62	Saquinavir	Human Immunodeficiency Virus (HIV) Infection	[11]
Tenofovir disoproxil + Maraviroc	DCJJLVE	Tenofovir disoproxil	HIV-1-infection	[12]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 806).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] ClinicalTrials.gov (NCT00977756) IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
• [4] ClinicalTrials.gov (NCT02961829) Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
• [5] ClinicalTrials.gov (NCT01505114) Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
• [6] ClinicalTrials.gov (NCT00853840) Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
• [7] ClinicalTrials.gov (NCT00993148) Maraviroc Plus Darunavir/Ritonavir for Treatment-Nave Patients Infected With R5-tropic HIV-1
• [8] ClinicalTrials.gov (NCT02799888) Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
• [9] ClinicalTrials.gov (NCT02208037) Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
• [10] ClinicalTrials.gov (NCT02519777) Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
• [11] ClinicalTrials.gov (NCT00717067) Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
• [12] ClinicalTrials.gov (NCT04965662) The Role of Home Packs of HIV PEPSE in High Risk Individuals